Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: Long-term results of a pilot phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 11-18

  Ghosn, Marwan ^a   Kattan, Joseph ^a   Farhat, Fadi ^b   Younes, Fariha ^a   Nasr, Fadi ^a   Moukadem, Walid ^c   Gasmi, Jamal ^d   Chahine, Georges ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b Hammoud Hospital   (Lebanon)

^c Haikal Hospital   (Lebanon)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Capecitabine; Chemotherapy; Docetaxel; First line; Metastatic breast cancer; Navcap; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DOCETAXEL; NAVELBINE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN DISEASE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PILOT PROJECTS; SAMPLE SIZE; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 42149137944     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0565-x     Document Type: Article

References (38)

1. Mariani G (2005) New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol 16(suppl 2):ii191-ii194
2. Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617-632
3. Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252
4. Berruti A, Sperone P, Bottini A et al (2000) Phase II study of protracted fluorouracil infusion as second or third-line approach for advanced breast cancer patients previously treated with anthracycline. J Clin Oncol 18:3370-3377
5. Aboul Enein M, Moussa M, Sabri A et al (2004) Vinorelbine-5 fluorouracil combination as first line chemotherapy in anthracycline pretreated patients with metastatic breast cancer. Ann Oncol 15(S3):47 (Abstr 177P)
6. Nole F, De Braud F, Aapro M et al (1997) Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 8:865-870
7. Dieras V, Extra JM, Bellissant E et al (1996) Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 14:3097-3104
8. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485-494
9. Blum JL, Dieras V, Lorusso PM et al (2001) Multicenter phase II study of oral capecitabine in taxane-pretreated metastatic breast cancer. Cancer 92:1759-1768
10. O'Shaughnessy J, Blum J, Moiseyenko V et al (2001) Randomised open-label, phase II trial of oral capecitabine (xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254
11. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
12. Welt G. von Minckwitz, Oberhof C et al (2005) Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16:64-69
13. Jin-Hee Ahn, Sung-Bae Kim, Tae-Won Kim et al (2004) Capecitabine and Vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19:547-553
14. Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J (2006) Phase II trial of capecitabine and Vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26(3):2451-2456
15. Burstein HJ, Manola J, Younger J et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219
16. Gennari A, Guarneri V, Landucci E, et al., Eniu A, Palmieri FM, Perez EA et al (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10(9):665-685
17. Saintigny P, Assouad S, Gligorov J et al (2004) Dose density and dose intensity in the treatment of breast cancer. Bull du cancer 91(suppl 4):S244-S253
18. Rodenhuis S (2000) The status of high-dose chemotherapy in breast cancer. Oncologist 5(5):369-375
19. Soto C, Torrecillas L, Reyes S et al (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential versus combined therapy results from a MOSG randomized phase III trial. Supplement to Journal of Clinical Oncology, 24 (18S), part I of II, p 20s, (abstract 570)
20. Conte PF, Guarneri V, Bruzzi P et al (2004) Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101(4):704-712
21. Alba E, Martin M, Ramos M (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish breast cancer research group (GEICAM-9903) phase III study. J Clin Oncol 22(13):2587-2593
22. Cresta S, Grasselli G, Mansutti M et al (2004) A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 15(3):433-439
23. Beslija S, Obralic N, Basic H et al (2006) Randomized trial of sequence versus combination of capecitabine (X) and docetaxel (T): XT versus T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 24(18S), part I of II, p 20s, abstract 571
24. Fleming TR (1982) One-sample multiple testing procedures for phase II clinical trials. Biometrics 43:143-151
25. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - a phase II single-center study. J Clin Oncol 17(4):1127-1131
26. Tabernero J, Climent MA, Lluch A et al (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365
27. Riviera E, Mejia JA, Arun B et al (2006) Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: final results. Proc Am Soc Clin Oncol 24(18S), part I of II, p 21s, abstract 574
28. Jones SE, Erban J, Overmoyer B et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5434-5436
29. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812-2823
30. Moinpour C, Wu J, Donaldson G, Liepa A et al (2004) Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(14S) (July 15 Supplement):621
31. Beslija S, Obralic N, Basic H et al (2006) Randomized trial of sequence versus combination of capecitabine (X) and docetaxel (T): XT versus T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 24(18S) (June 20 Supplement):571
32. Soto C, Torrecillas L, Reyes S et al (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential versus combined therapy results from a MOSG randomized phase III trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 24(18S) (June 20 Supplement):570
33. Nole F, de Braud F, Aapro M et al (1997) Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 8(9):865-870
34. Fuentes H, Calderillo G, Alexander F et al (2006) Phase II study of gemcitabine plus cisplatin in metastatic breast cancer. Anticancer Drugs 17(5):565-570
35. Ocana A, Hortobagyi GN, Esteva FJ (2006) Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer 6(6):495-504
36. Hochster HS, Vogel CL, Burman SL et al (2001) Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study. Oncologist 6(3):269-277
37. Burstein HJ, Manola J, Younger J et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18(6):1212-1219
38. Ramaswamy B, Elias AD, Kelbick NT et al (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12(10):3124-3129